Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(0.21)
# 4,096
Out of 4,732 analysts
5
Total ratings
20%
Success rate
-17.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Maintains: Overweight | $31 → $19 | $8.00 | +137.50% | 2 | Dec 19, 2024 | |
| XNCR Xencor | Initiates: Overweight | $37 | $19.24 | +92.31% | 1 | Dec 12, 2024 | |
| RCUS Arcus Biosciences | Initiates: Overweight | $29 | $14.03 | +106.70% | 1 | Oct 8, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $18.54 | +83.39% | 1 | May 3, 2024 |
iTeos Therapeutics
Dec 19, 2024
Maintains: Overweight
Price Target: $31 → $19
Current: $8.00
Upside: +137.50%
Xencor
Dec 12, 2024
Initiates: Overweight
Price Target: $37
Current: $19.24
Upside: +92.31%
Arcus Biosciences
Oct 8, 2024
Initiates: Overweight
Price Target: $29
Current: $14.03
Upside: +106.70%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $18.54
Upside: +83.39%